{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"19.0","upperLimit":"81.0","value":"50.0"},{"groupId":"OG001","lowerLimit":"4.3","upperLimit":"49.1","value":"26.7"},{"groupId":"OG002","lowerLimit":"29.0","upperLimit":"100.0","value":"66.7"},{"groupId":"OG003","lowerLimit":"32.6","upperLimit":"100.0","value":"75.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"4"}],"units":"Participants"}],"description":"Per the RECIST guideline v1.1 complete response is defined as the disappearance of all target lesions; any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\<10 mm. Partial response is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. No statistical testing was done due to early study termination.","dispersionType":"95% Confidence Interval","groups":[{"description":"Induction erlotinib for 12 weeks followed by chemotherapy (either cisplatin/etoposide or paclitaxel/carboplatin) and radiation therapy. Patients who have had no response (partial or complete) after 6 weeks of induction therapy start chemoradiation therapy immediately.","id":"OG000","title":"EGFR: Erlotinib"},{"description":"Chemotherapy (either cisplatin/etoposide or paclitaxel/carboplatin) and radiation therapy.","id":"OG001","title":"EGFR: No Erlotinib"},{"description":"Induction crizotinib for 12 weeks followed by chemotherapy (either cisplatin/etoposide or paclitaxel/carboplatin) and radiation therapy. Patients who have had no response (partial or complete) after 6 weeks of induction therapy start chemoradiation therapy immediately.","id":"OG002","title":"ALK: Crizotinib"},{"description":"Chemotherapy (either cisplatin/etoposide or paclitaxel/carboplatin) and radiation therapy.","id":"OG003","title":"ALK: No Crizotinib"}],"paramType":"NUMBER","populationDescription":"Eligible patients with disease assessment","reportingStatus":"POSTED","timeFrame":"From randomization to study termination. Maximum follow-up was 39.0 months","title":"Percentage of Patients With Complete or Partial Response","type":"SECONDARY","unitOfMeasure":"percentage of participants"}